Search

Displaying results 2261 - 2270 of 10000 in total
  1. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942] … Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  2. Target

    Matrix metalloproteinase-15

    go.drugbank.com/bio_entities/BE0003693
    TargetHumans

    Endopeptidase that degrades various components of the extracellular matrix. May activate progelatinase A

    Polypeptides: Matrix metalloproteinase-15Synonyms: MMP-15
  3. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.

    Mixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETSİZ
  4. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

  5. Drug

    Molybdate Mo-99

    go.drugbank.com/drugs/DB16587
    Investigational

    Salts: Sodium molybdate Mo-99Synonyms: Molybdate Mo 99, Molybdate Mo-99
  6. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]

    Products: UROKINASE-GREEN CROSS INJ. 60,000 iu/vial, UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADET
  7. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces erythropoiesis. … Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  8. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). … CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.

  9. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS). … RPI-78M is being developed for the treatment of multiple sclerosis (MS).

  10. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary